{"doc":{"info":{"calaisRequestID":"98fe0175-dded-888b-15e8-c3621313a98f","id":"http:\/\/id.opencalais.com\/saj3yMHPpRid4tCKbiD3yA","ontology":"http:\/\/mdaas-virtual-onecalais.int.thomsonreuters.com\/owlschema\/11.0\/onecalais.owl.allmetadata.xml","docId":"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160","document":"Liquid Biopsy Market by Cancer Type, by Sample Type, by Diagnostic Approach, By End Users and by Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016-2021)(EMAILWIRE.COM, September 16, 2017 ) The Global Liquid Biopsy market is expected to increase at a CAGR of 24.3% in the forecast period of 2016-2021 and reach a value of USD 1.75 billion by 2021 from USD 590.2 million in 2016.\n\nThis technology of liquid biopsy industry has enormous diagnostic and treatment implications for oncology and it is believed to transform clinical practice. A liquid biopsy, may capture the entire heterogeneity of the disease. This methodology is advantageous over tissue biopsies as monitoring of tumour genomic can be done by taking serial samples.\n\nBrowse market data tables and in-depth TOC of the Global Liquid Biopsy Industry to 2021 @ http:\/\/www.marketdataforecast.com\/market-reports\/global-liquid-biopsy-market-950\/\n\nForemost drivers for the liquid biopsy market include. Liquid biopsies are adopted due to the factors such as tolerability and patient convenience. Tissue biopsies cannot be done for few non-small cell lung cancers and liquid biopsy procedures are replacing tissue diagnosis procedures in such cases. Liquid biopsy research process involves a large amount of money and frequent clinical trials which is acting as a restraint for the market growth.\n\nFree sample of the report is available @ http:\/\/www.marketdataforecast.com\/market-reports\/global-liquid-biopsy-market-950\/request-sample\n\nthe liquid biopsy market is mainly segmented by types of cancer into Lung Cancer, Pancreatic Cancer, Leukemia and Other Visceral Cancers. By Diagnostic approach they can be classified as Circulating Tumour cells (CTC), Circulating Tumour DNA (ctDNA), RNA in exosomes and Extra-Cellular Vesicles. Based on end users, the market is segmented into reference laboratories, hospital\/physician laboratories, academic and research centers, and other end users. The market is bifurcate into blood, urine, plasma, saliva and Cerebrospinal fluid based upon sample type. CTCs (Circulating Tumour cells), the first such entities on the liquid biopsy scene, have accounted for a large share in the market. Cancer institute is the largest end user segment in terms of revenues and is expected to create substantial opportunity in global liquid biopsy market over the forecast period.\n\nGeographically the market is segmented into North America (U.S.A. and Canada), Europe (U.K., Germany, Italy, France, and Spain), Asia-Pacific (India, China, Australia, South Korea and Japan), Latin America (Mexico, Argentina and Brazil), Middle East and Africa. All major action in the field of liquid biopsy is expected to emerge from North America and Europe region over the forecast period. However, increasing funding for private public partnerships in field of cancer research is expected to fuel the Asia-Pacific Market.\n\nInquire before Buying at http:\/\/www.marketdataforecast.com\/market-reports\/global-liquid-biopsy-market-950\/inquire\n\nThe key players dominating the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.\n\nAbout Us:\n\nMarket Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.\n\nVisit Market Data Forecast Blog @ http:\/\/www.marketdataforecast.com\/blog\/\n\nView latest Press Releases of MDF @ http:\/\/www.marketdataforecast.com\/press-releases","docTitle":"","docDate":"2017-09-16 19:41:51.868"},"meta":{"contentType":"text\/raw","processingVer":"AllMetadata","serverVersion":"OneCalais_11.0-RELEASE:169","stagsVer":"OneCalais_11.0-RELEASE-b10-2017-07-31_12:36:53","submissionDate":"2017-09-16 19:41:51.281","submitterCode":"0ca6a864-5659-789d-5f32-f365f695e757","signature":"digestalg-1|12bGdN+6ZS3t5jlcatLaMeaCXnc=|Ob2iHEBjiS3ANfvtZ9ARVq7g5uoHiCAAKn6WIvVEGv0EfPauTO5GBQ==","language":"English"}},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/cat\/1":{"_typeGroup":"topics","forenduserdisplay":"false","score":1,"name":"Health_Medical_Pharma"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/cat\/2":{"_typeGroup":"topics","forenduserdisplay":"false","score":0.81,"name":"Business_Finance"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/lid\/DefaultLangId":{"_typeGroup":"language","language":"http:\/\/d.opencalais.com\/lid\/DefaultLangId\/English","forenduserdisplay":"false","permid":"505062"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/1":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/1","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/5f34e2d5-9b90-3695-8854-40c95b0b235f","forenduserdisplay":"true","name":"Medicine","importance":"1","originalValue":"Medicine"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/2":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/2","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/13f9a799-4d99-3b8a-9a54-37291840345a","forenduserdisplay":"true","name":"Clinical medicine","importance":"1","originalValue":"Clinical medicine"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/3":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/3","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/ec85c79c-9beb-3ec8-9cbc-0c21fab8f20d","forenduserdisplay":"true","name":"Biopsy","importance":"1","originalValue":"Biopsy"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/4":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/4","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/f3ef0a86-17a6-3537-b83d-55d9750adf54","forenduserdisplay":"true","name":"Liquid biopsy","importance":"2","originalValue":"Liquid biopsy"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/5":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/5","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/a4ea53dc-8a37-3c40-abb1-d09ca2886b6f","forenduserdisplay":"true","name":"Circulating tumor DNA","importance":"2","originalValue":"Circulating tumor DNA"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/6":{"_typeGroup":"socialTag","id":"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/SocialTag\/6","socialTag":"http:\/\/d.opencalais.com\/genericHasher-1\/acc92a07-4231-3285-b9bc-d33da6954fa9","forenduserdisplay":"true","name":"Qiagen","importance":"2","originalValue":"Qiagen"},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/1":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Diagnostic & Testing Substances Manufacturers","rcscode":"B:1732","permid":"4294951269","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/2":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Medical & Diagnostic Laboratories","rcscode":"B:1722","permid":"4294951279","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/3":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Specialty & Advanced Pharmaceuticals","rcscode":"B:1730","permid":"4294951271","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/4":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Market Research","rcscode":"B:1444","permid":"4294951557","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/5":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Biotechnology & Medical Research - NEC","rcscode":"B:1736","permid":"4294951265","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/6":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Bio Medical Devices","rcscode":"B:1739","permid":"4294951262","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/7":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Advanced Medical Equipment & Technology - NEC","rcscode":"B:1700","permid":"4294951301","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/8":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Diagnostic & Testing Substances","rcscode":"B:1714","permid":"4294951287","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/Industry\/9":{"_typeGroup":"industry","forenduserdisplay":"false","name":"Medical Diagnostic & Testing Equipment","rcscode":"B:1701","permid":"4294951300","relevance":0.2},"http:\/\/d.opencalais.com\/dochash-1\/6d9caf28-78ad-3092-8db3-2fd14d1fd160\/ComponentVersions":{"_typeGroup":"versions","version":["DIY-Categorization-fnr-TRCS-capx:20170627191152:20170627191152","Deals Index:201709161922:201709161922","DIY-Categorization-fnr-TRCS-indx_stsale:20170323110805:20170323110805","DIY-Categorization-fnr-TRCS-comptn:20170621141739:20170621141739","index-refineries:201705201529:201705201529","DIY-Categorization-fnr-TRCS-regs_buyb_new:20170509091609:20170509091609","config-physicalAssets-powerStations:653:653","NextTags:OneCalais_11.0-RELEASE:169","DIY-Categorization-fnr-TRCS-dis:20170418132337:20170418132337","DIY-Categorization-fnr-TRCS-splitb_r1:20170329082516:20170329082516","config-sca-DataPackage:50:50","config-companyNe:655:655","DIY-Categorization-fnr-TRCS-acb:20170502102348:20170502102348","DIY-Categorization-fnr-TRCS-levrge:20170621122109:20170621122109","DIY-Categorization-fnr-TRCS-hedge_list1:20170315123823:20170315123823","config-refreshableDIY:1:1","People Index:201709161932:201709161932","config-negativeSignature:653:653","DIY-Categorization-fnr-TRCS-fake1_monop_bnkcap_new:20170405133257:20170405133257","Dial4J:OneCalais_8.6-RELEASE:209","DIY-Categorization-fnr-TRCS-dbtr_new:20170315123740:20170315123740","OA Override:672:672","DIY-Categorization-fnr-TRCS-hrgt:20170427081548:20170427081548","DIY-Categorization-fnr-TRCS-xpand:20170323144646:20170323144646","DIY-Categorization-fnr-TRCS-allcemrgdvst2:20170316142831:20170316142831","DIY-Categorization-fnr-TRCS-ordr:20170313151239:20170313151239","People Override:653:653","DIY-Categorization-fnr-TRCS-hrgt_recll:20170522120000:20170522120000","index-company-oa3:201709152017:201709152017","index-vessels:201709091437:201709091437","DIY-Categorization-fnr-TRCS-brib_r1:20170329090629:20170329090629","config-forEndUserDisplay:3:3","config-refineries:653:653","DIY-Categorization-fnr-TRCS-fapm:20170713144316:20170713144316","DIY-Categorization-fnr-TRCS-class:20170315123207:20170315123207","config-cse:672:672","DIY-Categorization-fnr-TRCS-isu_dat_r:20170315124144:20170315124144","DIY-Categorization-fnr-TRCS-cnsl_sisu:20170321144134:20170321144134","DIY-Categorization-fnr-TRCS-shract_r1:20170412111808:20170412111808","config-vessels:653:653","OneCalais:OneCalais_11.0-RELEASE:169","DIY-Categorization-fnr-TRCS-mktshr2:20170705120412:20170705120412","DIY-RCS-fnr-TRCS-cavs:4:4","DIY-Categorization-fnr-TRCS-trd_tax:20170309132522:20170309132522","DIY-Categorization-fnr-TRCS-sov_2:20170522130956:20170522130956","DIY-Categorization-fnr-TRCS-bons:20170406103713:20170406103713","DIY-RCS-fnr-TRCS-nd:3:3","DIY-Categorization-fnr-TRCS-stx:20170530123138:20170530123138","config-physicalAssets-mines:653:653","SocialTags Index:201709040612:201709040612","BlackList:672:672","index-ports:201709091455:201709091455","config-physicalAssets-ports:653:653","DIY-Categorization-fnr-TRCS-ream:20170529065740:20170529065740","DIY-Categorization-fnr-TRCS-chld:20170524084254:20170524084254","DIY-Categorization-fnr-TRCS-allce:20170323145654:20170323145654","DIY-Categorization-fnr-TRCS-medreg:20170508120210:20170508120210","config-drugs:653:653"]},"http:\/\/d.opencalais.com\/comphash-1\/e4e9a83e-f4d5-3551-8375-d99835801ec1":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Qiagen","nationality":"N\/A","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[liquid biopsy market are Janssen Diagnostics, ]Qiagen[, Rarecells SAS, Silicon Biosystems, SRI]","prefix":"liquid biopsy market are Janssen Diagnostics, ","exact":"Qiagen","suffix":", Rarecells SAS, Silicon Biosystems, SRI","offset":3116,"length":6}],"relevance":0.2,"resolutions":[{"name":"Qiagen N.V.","permid":"4295884717","primaryric":"QGEN.OQ","ispublic":"true","commonname":"Qiagen","score":0.9776135,"id":"https:\/\/permid.org\/1-4295884717","ticker":"QGEN"}],"confidence":{"statisticalfeature":"0.843","dblookup":"0.0","resolution":"0.9776135","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/comphash-1\/0dce8fb4-b8c6-350c-be0a-2bff012bf2f5":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"SRI International","nationality":"N\/A","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[Qiagen, Rarecells SAS, Silicon Biosystems, ]SRI International[, Myriad Genetics, Natera, Personal Genome]","prefix":"Qiagen, Rarecells SAS, Silicon Biosystems, ","exact":"SRI International","suffix":", Myriad Genetics, Natera, Personal Genome","offset":3159,"length":17}],"relevance":0.2,"resolutions":[{"name":"SRI INTERNATIONAL","permid":"4296599682","ispublic":"false","commonname":"SRI","score":0.40816954,"id":"https:\/\/permid.org\/1-4296599682"}],"confidence":{"statisticalfeature":"0.929","dblookup":"0.0","resolution":"0.40816954","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/genericHasher-1\/398f0f7f-7b2f-3363-bda4-f09b836ed062":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Germany","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[ North America (U.S.A. and Canada), Europe (U.K., ]Germany[, Italy, France, and Spain), Asia-Pacific (India,]","prefix":" North America (U.S.A. and Canada), Europe (U.K., ","exact":"Germany","suffix":", Italy, France, and Spain), Asia-Pacific (India,","offset":2489,"length":7}],"relevance":0.2,"resolutions":[{"name":"Germany","shortname":"Germany","latitude":"51.0","longitude":"9.0","rcscode":"G:3D","permid":"100114"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/4b3b67f8-9145-3ceb-9bb5-ecffd1f7d8c5":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Leukemia","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[of cancer into Lung Cancer, Pancreatic Cancer, ]Leukemia[ and Other Visceral Cancers. By Diagnostic]","prefix":"of cancer into Lung Cancer, Pancreatic Cancer, ","exact":"Leukemia","suffix":" and Other Visceral Cancers. By Diagnostic","offset":1626,"length":8}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/4bf38dc8-d260-3e55-99dd-548078d7d09d":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"silicon biosystems","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[are Janssen Diagnostics, Qiagen, Rarecells SAS, ]Silicon Biosystems[, SRI International, Myriad Genetics, Natera,]","prefix":"are Janssen Diagnostics, Qiagen, Rarecells SAS, ","exact":"Silicon Biosystems","suffix":", SRI International, Myriad Genetics, Natera,","offset":3139,"length":18}],"relevance":0.2,"confidence":{"statisticalfeature":"0.668","dblookup":"0.0","resolution":"0.27610335","aggregate":"1.0"},"resolutions":[{"name":"Silicon Biosystems S.p.A","permid":"4297890776","ispublic":"false","commonname":"Silicon","score":0.27610335,"id":"https:\/\/permid.org\/1-4297890776"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/ae7bd5ec-9003-37ff-98df-282343699393":{"_typeGroup":"entities","_type":"URL","forenduserdisplay":"false","name":"http:\/\/www.marketdataforecast.com\/press-releases","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/URL","instances":[{"detection":"[latest Press Releases of MDF @ ]http:\/\/www.marketdataforecast.com\/press-releases[]","prefix":"latest Press Releases of MDF @ ","exact":"http:\/\/www.marketdataforecast.com\/press-releases","offset":3850,"length":48}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/df18b91e-c25b-391d-a552-c9ae71e627e0":{"_typeGroup":"entities","_type":"Region","forenduserdisplay":"false","name":"Latin America","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Region","instances":[{"detection":"[China, Australia, South Korea and Japan), ]Latin America[ (Mexico, Argentina and Brazil), Middle East and]","prefix":"China, Australia, South Korea and Japan), ","exact":"Latin America","suffix":" (Mexico, Argentina and Brazil), Middle East and","offset":2588,"length":13}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/92a95ab9-3361-3cf5-a2f2-fb478ccedf08":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"NATERA","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[Biosystems, SRI International, Myriad Genetics, ]Natera[, Personal Genome Diagnostics, Sysmex Inostics,]","prefix":"Biosystems, SRI International, Myriad Genetics, ","exact":"Natera","suffix":", Personal Genome Diagnostics, Sysmex Inostics,","offset":3195,"length":6}],"relevance":0.2,"confidence":{"statisticalfeature":"0.644","dblookup":"0.0","resolution":"0.7965721","aggregate":"1.0"},"resolutions":[{"name":"NATERA, INC.","permid":"5032036738","primaryric":"NTRA.OQ","ispublic":"true","commonname":"Natera","score":0.7965721,"id":"https:\/\/permid.org\/1-5032036738","ticker":"NTRA"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/142c6072-e482-3db0-84ee-44bb9df61316":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Cancer","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[Liquid Biopsy Market by ]Cancer[ Type, by Sample Type, by Diagnostic Approach, By]","prefix":"Liquid Biopsy Market by ","exact":"Cancer","suffix":" Type, by Sample Type, by Diagnostic Approach, By","offset":24,"length":6},{"detection":"[biopsy market is mainly segmented by types of ]cancer[ into Lung Cancer, Pancreatic Cancer, Leukemia]","prefix":"biopsy market is mainly segmented by types of ","exact":"cancer","suffix":" into Lung Cancer, Pancreatic Cancer, Leukemia","offset":1582,"length":6},{"detection":"[have accounted for a large share in the market. ]Cancer[ institute is the largest end user segment in]","prefix":"have accounted for a large share in the market. ","exact":"Cancer","suffix":" institute is the largest end user segment in","offset":2218,"length":6},{"detection":"[for private public partnerships in field of ]cancer[ research is expected to fuel the Asia-Pacific]","prefix":"for private public partnerships in field of ","exact":"cancer","suffix":" research is expected to fuel the Asia-Pacific","offset":2862,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/16c509a2-c9c1-3a78-b49f-ef0e5a0124de":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"disease","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[may capture the entire heterogeneity of the ]disease[. This methodology is advantageous over tissue]","prefix":"may capture the entire heterogeneity of the ","exact":"disease","suffix":". This methodology is advantageous over tissue","offset":631,"length":7}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/7e74eee0-7650-3126-b1e9-746efbc103cf":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Sysmex Inostics","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[Genetics, Natera, Personal Genome Diagnostics, ]Sysmex Inostics[, Trovagene, Exosome Diagnostics, Exosome]","prefix":"Genetics, Natera, Personal Genome Diagnostics, ","exact":"Sysmex Inostics","suffix":", Trovagene, Exosome Diagnostics, Exosome","offset":3232,"length":15}],"relevance":0.2,"resolutions":[{"name":"Sysmex Inostics GmbH","permid":"5038054438","ispublic":"false","commonname":"Sysmex Inostics","score":0.17060874,"id":"https:\/\/permid.org\/1-5038054438"}],"confidence":{"statisticalfeature":"0.668","dblookup":"0.0","resolution":"0.17060874","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/genericHasher-1\/e1fd0a20-f464-39be-a88f-25038cc7f50c":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"France","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[and Canada), Europe (U.K., Germany, Italy, ]France[, and Spain), Asia-Pacific (India, China,]","prefix":"and Canada), Europe (U.K., Germany, Italy, ","exact":"France","suffix":", and Spain), Asia-Pacific (India, China,","offset":2505,"length":6}],"relevance":0.2,"resolutions":[{"name":"France","shortname":"France","latitude":"46.0","longitude":"2.0","rcscode":"G:5M","permid":"100105"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/ed1c9b63-4b8e-311f-b8db-0f90ea812660":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Japan","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[(India, China, Australia, South Korea and ]Japan[), Latin America (Mexico, Argentina and Brazil),]","prefix":"(India, China, Australia, South Korea and ","exact":"Japan","suffix":"), Latin America (Mexico, Argentina and Brazil),","offset":2580,"length":5}],"relevance":0.2,"resolutions":[{"name":"Japan","shortname":"Japan","latitude":"35.4111749285","longitude":"135.833685568","rcscode":"G:41","permid":"100148"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/ec2783a6-5e83-3e83-ad4b-e1e5f8472541":{"_typeGroup":"entities","_type":"Technology","forenduserdisplay":"false","name":"technology of liquid biopsy industry","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Technology","instances":[{"detection":"[by 2021 from USD 590.2 million in 2016.\n\nThis ]technology of liquid biopsy industry[ has enormous diagnostic and treatment]","prefix":"by 2021 from USD 590.2 million in 2016.\n\nThis ","exact":"technology of liquid biopsy industry","suffix":" has enormous diagnostic and treatment","offset":418,"length":36}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/27764afc-5998-309c-829d-67e3fb3faf4f":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Exosome Diagnostics","nationality":"N\/A","confidencelevel":"1.0","confidence":{"statisticalfeature":"0.942","dblookup":"0.0","resolution":"0.2618867","aggregate":"1.0"},"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[Genome Diagnostics, Sysmex Inostics, Trovagene, ]Exosome Diagnostics[, Exosome Sciences, and HansaBiomed OU.\n\nAbout]","prefix":"Genome Diagnostics, Sysmex Inostics, Trovagene, ","exact":"Exosome Diagnostics","suffix":", Exosome Sciences, and HansaBiomed OU.\n\nAbout","offset":3260,"length":19}],"relevance":0.2,"resolutions":[{"name":"EXOSOME DIAGNOSTICS, INC.","permid":"5000738181","ispublic":"false","commonname":"EXOSOME","score":0.2618867,"id":"https:\/\/permid.org\/1-5000738181"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/a54ac18b-a956-3b5c-b235-0609ca899305":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"United States","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[the market is segmented into North America (]U.S.A.[ and Canada), Europe (U.K., Germany, Italy,]","prefix":"the market is segmented into North America (","exact":"U.S.A.","suffix":" and Canada), Europe (U.K., Germany, Italy,","offset":2455,"length":6}],"relevance":0.2,"resolutions":[{"name":"United States","shortname":"United States","latitude":"40.4230003233","longitude":"-98.7372244786","rcscode":"G:6J","permid":"100319"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/37f0cf6b-b991-3dc8-8018-78338494cd3a":{"_typeGroup":"entities","_type":"Continent","forenduserdisplay":"false","name":"North America","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Continent","instances":[{"detection":"[the market is segmented into ]North America[ (U.S.A. and Canada), Europe (U.K., Germany,]","prefix":"the market is segmented into ","exact":"North America","suffix":" (U.S.A. and Canada), Europe (U.K., Germany,","offset":2440,"length":13},{"detection":"[of liquid biopsy is expected to emerge from ]North America[ and Europe region over the forecast period.]","prefix":"of liquid biopsy is expected to emerge from ","exact":"North America","suffix":" and Europe region over the forecast period.","offset":2732,"length":13}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/fe313a08-88a6-33a7-980f-410dd8e740a6":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Brazil","resolutions":[{"name":"Brazil","shortname":"Brazil","latitude":"-15.6777731062","longitude":"-47.4383649658","rcscode":"G:26","permid":"100042"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[ and Japan), Latin America (Mexico, Argentina and ]Brazil[), Middle East and Africa. All major action in]","prefix":" and Japan), Latin America (Mexico, Argentina and ","exact":"Brazil","suffix":"), Middle East and Africa. All major action in","offset":2625,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/4f483ad3-ec52-340b-aa12-c53d88ebfd09":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"tumour","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[over tissue biopsies as monitoring of ]tumour[ genomic can be done by taking serial]","prefix":"over tissue biopsies as monitoring of ","exact":"tumour","suffix":" genomic can be done by taking serial","offset":711,"length":6},{"detection":"[approach they can be classified as Circulating ]Tumour[ cells (CTC), Circulating Tumour DNA (ctDNA), RNA]","prefix":"approach they can be classified as Circulating ","exact":"Tumour","suffix":" cells (CTC), Circulating Tumour DNA (ctDNA), RNA","offset":1724,"length":6},{"detection":"[as Circulating Tumour cells (CTC), Circulating ]Tumour[ DNA (ctDNA), RNA in exosomes and Extra-Cellular]","prefix":"as Circulating Tumour cells (CTC), Circulating ","exact":"Tumour","suffix":" DNA (ctDNA), RNA in exosomes and Extra-Cellular","offset":1756,"length":6},{"detection":"[fluid based upon sample type. CTCs (Circulating ]Tumour[ cells), the first such entities on the liquid]","prefix":"fluid based upon sample type. CTCs (Circulating ","exact":"Tumour","suffix":" cells), the first such entities on the liquid","offset":2103,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/3318e567-b14a-3778-b3e5-a2fec0e41e57":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"TrovaGene","confidencelevel":"1.0","resolutions":[{"name":"TROVAGENE, INC.","permid":"4296438979","primaryric":"TROV.OQ","ispublic":"true","commonname":"Trovagene","score":0.8680883,"id":"https:\/\/permid.org\/1-4296438979","ticker":"TROV"}],"confidence":{"statisticalfeature":"0.644","dblookup":"0.0","resolution":"0.8680883","aggregate":"1.0"},"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[Personal Genome Diagnostics, Sysmex Inostics, ]Trovagene[, Exosome Diagnostics, Exosome Sciences, and]","prefix":"Personal Genome Diagnostics, Sysmex Inostics, ","exact":"Trovagene","suffix":", Exosome Diagnostics, Exosome Sciences, and","offset":3249,"length":9}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/09bebb87-1ef5-373d-bd01-263e77470c65":{"_typeGroup":"entities","_type":"Continent","forenduserdisplay":"false","name":"Europe","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Continent","instances":[{"detection":"[into North America (U.S.A. and Canada), ]Europe[ (U.K., Germany, Italy, France, and Spain),]","prefix":"into North America (U.S.A. and Canada), ","exact":"Europe","suffix":" (U.K., Germany, Italy, France, and Spain),","offset":2475,"length":6},{"detection":"[is expected to emerge from North America and ]Europe[ region over the forecast period. However,]","prefix":"is expected to emerge from North America and ","exact":"Europe","suffix":" region over the forecast period. However,","offset":2750,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/1e6020d8-17bc-3ade-92df-3b993ac84a0a":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Italy","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[(U.S.A. and Canada), Europe (U.K., Germany, ]Italy[, France, and Spain), Asia-Pacific (India, China,]","prefix":"(U.S.A. and Canada), Europe (U.K., Germany, ","exact":"Italy","suffix":", France, and Spain), Asia-Pacific (India, China,","offset":2498,"length":5}],"relevance":0.2,"resolutions":[{"name":"Italy","shortname":"Italy","latitude":"44.2632","longitude":"11.4402833333","rcscode":"G:5J","permid":"100145"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/243ebc43-e0ad-3a07-9bc7-2d6d599052f4":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Canada","resolutions":[{"name":"Canada","shortname":"Canada","latitude":"56.757746527","longitude":"-86.4195625771","rcscode":"G:8W","permid":"100052"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[is segmented into North America (U.S.A. and ]Canada[), Europe (U.K., Germany, Italy, France, and]","prefix":"is segmented into North America (U.S.A. and ","exact":"Canada","suffix":"), Europe (U.K., Germany, Italy, France, and","offset":2466,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/84a34c48-25ac-327f-a805-7b81fd570f7d":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Australia","resolutions":[{"name":"Australia","shortname":"Australia","latitude":"-32.34562","longitude":"141.434598022","rcscode":"G:2H","permid":"100025"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[France, and Spain), Asia-Pacific (India, China, ]Australia[, South Korea and Japan), Latin America (Mexico,]","prefix":"France, and Spain), Asia-Pacific (India, China, ","exact":"Australia","suffix":", South Korea and Japan), Latin America (Mexico,","offset":2553,"length":9}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/23a2d531-562d-36f1-b765-900ae5bb78a1":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"few non-small cell lung cancers","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[convenience. Tissue biopsies cannot be done for ]few non-small cell lung cancers[ and liquid biopsy procedures are replacing]","prefix":"convenience. Tissue biopsies cannot be done for ","exact":"few non-small cell lung cancers","suffix":" and liquid biopsy procedures are replacing","offset":1121,"length":31}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/3ed8c7d6-11ae-3003-9516-010c438ae440":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Lung Cancer","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[is mainly segmented by types of cancer into ]Lung Cancer[, Pancreatic Cancer, Leukemia and Other Visceral]","prefix":"is mainly segmented by types of cancer into ","exact":"Lung Cancer","suffix":", Pancreatic Cancer, Leukemia and Other Visceral","offset":1594,"length":11}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/55ccb46b-68ce-3750-a326-6bdd742672fc":{"_typeGroup":"entities","_type":"Region","forenduserdisplay":"false","name":"Middle East","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Region","instances":[{"detection":"[Latin America (Mexico, Argentina and Brazil), ]Middle East[ and Africa. All major action in the field of]","prefix":"Latin America (Mexico, Argentina and Brazil), ","exact":"Middle East","suffix":" and Africa. All major action in the field of","offset":2634,"length":11}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/cc88b155-205c-3676-a151-d45f473f0b16":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"United Kingdom","resolutions":[{"name":"United Kingdom","shortname":"United Kingdom","latitude":"53.1142456495","longitude":"-2.57711368423","rcscode":"G:7J","permid":"100317"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[into North America (U.S.A. and Canada), Europe (]U.K.[, Germany, Italy, France, and Spain),]","prefix":"into North America (U.S.A. and Canada), Europe (","exact":"U.K.","suffix":", Germany, Italy, France, and Spain),","offset":2483,"length":4}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/19cc1d3f-0865-39b0-b3d6-b3739cf3e66a":{"_typeGroup":"entities","_type":"Continent","forenduserdisplay":"false","name":"Africa","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Continent","instances":[{"detection":"[(Mexico, Argentina and Brazil), Middle East and ]Africa[. All major action in the field of liquid biopsy]","prefix":"(Mexico, Argentina and Brazil), Middle East and ","exact":"Africa","suffix":". All major action in the field of liquid biopsy","offset":2650,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/3d1db47c-b851-32ab-af0b-0bffa4dad5d1":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"China","resolutions":[{"name":"China","shortname":"China","latitude":"32.9042932784","longitude":"110.467708512","rcscode":"G:B1","permid":"100064"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[Italy, France, and Spain), Asia-Pacific (India, ]China[, Australia, South Korea and Japan), Latin]","prefix":"Italy, France, and Spain), Asia-Pacific (India, ","exact":"China","suffix":", Australia, South Korea and Japan), Latin","offset":2546,"length":5}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/72c1c4dd-baf4-3279-92b0-dc5f71718dc1":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Personal Genome Diagnostics","nationality":"N\/A","confidencelevel":"1.0","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[SRI International, Myriad Genetics, Natera, ]Personal Genome Diagnostics[, Sysmex Inostics, Trovagene, Exosome]","prefix":"SRI International, Myriad Genetics, Natera, ","exact":"Personal Genome Diagnostics","suffix":", Sysmex Inostics, Trovagene, Exosome","offset":3203,"length":27}],"relevance":0.2,"confidence":{"statisticalfeature":"0.934","dblookup":"0.0","resolution":"0.26187244","aggregate":"1.0"},"resolutions":[{"name":"PERSONAL GENOME DIAGNOSTICS INC.","permid":"5039610342","ispublic":"false","commonname":"PGDx","score":0.26187244,"id":"https:\/\/permid.org\/1-5039610342"}]},"http:\/\/d.opencalais.com\/genericHasher-1\/a12b43d5-d195-35ea-96a9-f710943bdb5a":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"analyst","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[of both individual and corporate clients. Our ]analyst[ team comprises expert professionals in market]","prefix":"of both individual and corporate clients. Our ","exact":"analyst","suffix":" team comprises expert professionals in market","offset":3562,"length":7}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/93c8efd3-e0a3-399f-9b77-e2d64814bcfd":{"_typeGroup":"entities","_type":"Region","forenduserdisplay":"false","name":"Asia-Pacific","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Region","instances":[{"detection":"[(U.K., Germany, Italy, France, and Spain), ]Asia-Pacific[ (India, China, Australia, South Korea and]","prefix":"(U.K., Germany, Italy, France, and Spain), ","exact":"Asia-Pacific","suffix":" (India, China, Australia, South Korea and","offset":2525,"length":12},{"detection":"[ field of cancer research is expected to fuel the ]Asia-Pacific[ Market.\n\nInquire before Buying at]","prefix":" field of cancer research is expected to fuel the ","exact":"Asia-Pacific","suffix":" Market.\n\nInquire before Buying at","offset":2902,"length":12}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/33a00dd1-4139-3444-b9f4-149624f332ea":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Argentina","resolutions":[{"name":"Argentina","shortname":"Argentina","latitude":"-34.0","longitude":"-64.0","rcscode":"G:60","permid":"100017"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[South Korea and Japan), Latin America (Mexico, ]Argentina[ and Brazil), Middle East and Africa. All major]","prefix":"South Korea and Japan), Latin America (Mexico, ","exact":"Argentina","suffix":" and Brazil), Middle East and Africa. All major","offset":2611,"length":9}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/92956dc3-4c11-340f-b4b5-1266cd1c7c5c":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Mexico","resolutions":[{"name":"Mexico","shortname":"Mexico","latitude":"19.0","longitude":"-99.0","rcscode":"G:2V","permid":"100184"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[South Korea and Japan), Latin America (]Mexico[, Argentina and Brazil), Middle East and Africa.]","prefix":"South Korea and Japan), Latin America (","exact":"Mexico","suffix":", Argentina and Brazil), Middle East and Africa.","offset":2603,"length":6}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/70304883-953a-37d8-8452-7f2301d6be83":{"_typeGroup":"entities","_type":"Position","forenduserdisplay":"false","name":"hospital\/physician","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Position","instances":[{"detection":"[ market is segmented into reference laboratories, ]hospital\/physician[ laboratories, academic and research centers, and]","prefix":" market is segmented into reference laboratories, ","exact":"hospital\/physician","suffix":" laboratories, academic and research centers, and","offset":1894,"length":18}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/ec8b7684-103d-3823-90ab-6f795fe6697b":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Other Visceral Cancers","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[Lung Cancer, Pancreatic Cancer, Leukemia and ]Other Visceral Cancers[. By Diagnostic approach they can be classified]","prefix":"Lung Cancer, Pancreatic Cancer, Leukemia and ","exact":"Other Visceral Cancers","suffix":". By Diagnostic approach they can be classified","offset":1639,"length":22}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/4629bb98-2174-34d0-9db3-27c1522d6426":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"Spain","resolutions":[{"name":"Spain","shortname":"Spain","latitude":"40.6985822539","longitude":"-3.29494619839","rcscode":"G:55","permid":"100280"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[Europe (U.K., Germany, Italy, France, and ]Spain[), Asia-Pacific (India, China, Australia, South]","prefix":"Europe (U.K., Germany, Italy, France, and ","exact":"Spain","suffix":"), Asia-Pacific (India, China, Australia, South","offset":2517,"length":5}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/51cc1098-eebf-3042-b55c-46117974d025":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"South Korea","resolutions":[{"name":"South Korea","shortname":"South Korea","latitude":"36.4692974125","longitude":"127.624277169","rcscode":"G:AE","permid":"100275"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[Spain), Asia-Pacific (India, China, Australia, ]South Korea[ and Japan), Latin America (Mexico, Argentina and]","prefix":"Spain), Asia-Pacific (India, China, Australia, ","exact":"South Korea","suffix":" and Japan), Latin America (Mexico, Argentina and","offset":2564,"length":11}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/bd9333da-7b82-3d22-b7a2-4be182223a37":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Janssen Diagnostics","nationality":"N\/A","confidencelevel":"1.0","confidence":{"statisticalfeature":"0.929","dblookup":"0.0","resolution":"0.26189166","aggregate":"1.0"},"resolutions":[{"name":"JANSSEN DIAGNOSTICS, LLC","permid":"4298017820","ispublic":"false","commonname":"Janssen","score":0.26189166,"id":"https:\/\/permid.org\/1-4298017820"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[players dominating the liquid biopsy market are ]Janssen Diagnostics[, Qiagen, Rarecells SAS, Silicon Biosystems, SRI]","prefix":"players dominating the liquid biopsy market are ","exact":"Janssen Diagnostics","suffix":", Qiagen, Rarecells SAS, Silicon Biosystems, SRI","offset":3095,"length":19}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/69b2e356-c1e7-3f3b-bab3-676f21d08e4d":{"_typeGroup":"entities","_type":"Country","forenduserdisplay":"true","name":"India","resolutions":[{"name":"India","shortname":"India","latitude":"21.7678895778","longitude":"78.8717605778","rcscode":"G:5B","permid":"100136"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Country","instances":[{"detection":"[Italy, France, and Spain), Asia-Pacific (]India[, China, Australia, South Korea and Japan), Latin]","prefix":"Italy, France, and Spain), Asia-Pacific (","exact":"India","suffix":", China, Australia, South Korea and Japan), Latin","offset":2539,"length":5}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/308e226e-e195-3de5-aaff-6f38d54293b3":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Myriad Genetics","nationality":"N\/A","confidencelevel":"1.0","confidence":{"statisticalfeature":"0.857","dblookup":"0.0","resolution":"0.9838554","aggregate":"1.0"},"resolutions":[{"name":"MYRIAD GENETICS, INC.","permid":"4295907228","primaryric":"MYGN.OQ","ispublic":"true","commonname":"Myriad Genetics","score":0.9838554,"id":"https:\/\/permid.org\/1-4295907228","ticker":"MYGN"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[SAS, Silicon Biosystems, SRI International, ]Myriad Genetics[, Natera, Personal Genome Diagnostics, Sysmex]","prefix":"SAS, Silicon Biosystems, SRI International, ","exact":"Myriad Genetics","suffix":", Natera, Personal Genome Diagnostics, Sysmex","offset":3178,"length":15}],"relevance":0.2},"http:\/\/d.opencalais.com\/comphash-1\/766b77f5-6279-3bcb-b263-4b455a119667":{"_typeGroup":"entities","_type":"Company","forenduserdisplay":"true","name":"Exosome Sciences","confidencelevel":"1.0","resolutions":[{"name":"Exosome Sciences, Inc.","permid":"5000784623","ispublic":"false","commonname":"Exosome Sciences","score":0.022077005,"id":"https:\/\/permid.org\/1-5000784623"}],"_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Company","instances":[{"detection":"[ Sysmex Inostics, Trovagene, Exosome Diagnostics, ]Exosome Sciences[, and HansaBiomed OU.\n\nAbout Us:\n\nMarket Data]","prefix":" Sysmex Inostics, Trovagene, Exosome Diagnostics, ","exact":"Exosome Sciences","suffix":", and HansaBiomed OU.\n\nAbout Us:\n\nMarket Data","offset":3281,"length":16}],"relevance":0.2,"confidence":{"statisticalfeature":"0.668","dblookup":"0.0","resolution":"0.022077005","aggregate":"1.0"}},"http:\/\/d.opencalais.com\/genericHasher-1\/cf6b8bb8-77c8-33d5-b212-e69bdccdf4e7":{"_typeGroup":"entities","_type":"Technology","forenduserdisplay":"false","name":"business intelligence","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/Technology","instances":[{"detection":"[firm working in the area of market research and ]business intelligence[. With rich experience in research across various]","prefix":"firm working in the area of market research and ","exact":"business intelligence","suffix":". With rich experience in research across various","offset":3405,"length":21}],"relevance":0.2},"http:\/\/d.opencalais.com\/genericHasher-1\/a5a2eafd-ab45-3e44-bcf5-d6267b090a1f":{"_typeGroup":"entities","_type":"MedicalCondition","forenduserdisplay":"false","name":"Pancreatic Cancer","_typeReference":"http:\/\/s.opencalais.com\/1\/type\/em\/e\/MedicalCondition","instances":[{"detection":"[segmented by types of cancer into Lung Cancer, ]Pancreatic Cancer[, Leukemia and Other Visceral Cancers. By]","prefix":"segmented by types of cancer into Lung Cancer, ","exact":"Pancreatic Cancer","suffix":", Leukemia and Other Visceral Cancers. By","offset":1607,"length":17}],"relevance":0.2}}